Results 221 to 230 of about 712,965 (355)
SYHA1813, A VEGFR and CSF1R Inhibitor, in Patients With Recurrent High‐Grade Gliomas: A Multicenter, Open‐Label Phase I Study
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective
Recurrent high‐grade gliomas have a poor prognosis and limited therapeutic options. This study aimed to evaluate the safety and efficacy of SYHA1813, a dual inhibitor of VEGFR and CSF1R, in patients with recurrent high‐grade gliomas.Zhuang Kang, Shenglan Li, Liang Wang, Qianxue Chen, Weiguo Hu, Ting Lei, Ying Mao, Jing Zhang, Xiaojun Xiang, Qiming Wang, Zhengwen He, Tao Sun, Yulei Wang, Mengqian Huang, Rong Zhang, Feng Chen, Wenbin Li +16 morewiley +1 more sourceImportancia de la revisión por pares en la construcción del conocimiento: una mirada desde la Revista Española de Nutrición Humana y Dietética
Revista Española de Nutrición Humana y DietéticaClaudia Andrea Troncoso Pantoja, Amparo Gamero, Patricio Pérez-Armijo, Edgar Pérez-Esteve, Fanny Petermann-Rocha, Tania Fernández-Villa, Macarena Lozano-Lorca, Alberto Pérez-López, Manuel Reing García-Galbis, Elena Carrillo-Alvarez, Malak Kouiti, Diego A. Bonilla, Evelina Apolinar-Jiménez, Edna Nava-González , Joel Girón-Hernández, Rafael Almendra-Pegueros +15 moredoaj +1 more sourceDiagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
Blood, 2017 H. Döhner, E. Estey, D. Grimwade, S. Amadori, F. Appelbaum, T. Büchner, H. Dombret, B. Ebert, P. Fenaux, R. Larson, R. Levine, F. Lo‐Coco, T. Naoe, D. Niederwieser, G. Ossenkoppele, M. Sanz, J. Sierra, M. Tallman, H. Tien, A. Wei, B. Löwenberg, C. Bloomfield +21 moresemanticscholar +1 more sourceDurability of Response to B‐Cell Maturation Antigen‐Directed mRNA Cell Therapy in Myasthenia Gravis
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective
We report the 12‐month follow‐up outcomes from a Phase 2 clinical trial (NCT04146051) evaluating Descartes‐08, a BCMA‐directed RNA chimeric antigen receptor T‐cell (rCAR‐T) therapy for refractory generalized myasthenia gravis (MG).Nizar Chahin, Gregory Sahagian, Marc H. Feinberg, C. Andrew Stewart, Christopher M. Jewell, Metin Kurtoglu, Miloš D. Miljković, Tuan Vu, Tahseen Mozaffar, James F. Howard Jr, the MG‐001 Study Group +10 morewiley +1 more sourceThe 2017 international classification of the Ehlers–Danlos syndromes
American Journal of Medical Genetics. Part C, Seminars in Medical Genetics, 2017 F. Malfait, C. Francomano, P. Byers, J. Belmont, B. Berglund, J. Black, Lara Bloom, J. Bowen, A. Brady, N. Burrows, M. Castori, H. Cohen, M. Colombi, S. Demirdas, J. De Backer, A. De Paepe, S. Fournel‐Gigleux, M. Frank, N. Ghali, C. Giunta, R. Grahame, A. Hakim, X. Jeunemaître, Diana S. Johnson, B. Juul-Kristensen, I. Kapferer-Seebacher, H. Kazkaz, T. Kosho, M. Lavallee, H. Levy, R. Mendoza-Londono, M. Pepin, F. Pope, E. Reinstein, L. Robert, M. Rohrbach, Lynn S Sanders, G. Sobey, Tim Van Damme, A. Vandersteen, C. van Mourik, N. Voermans, N. Wheeldon, J. Zschocke, B. Tinkle +44 moresemanticscholar +1 more source